Landos Biopharma, Inc. – NASDAQ:LABP
Landos Biopharma stock price today
$22.91
-0.01
-0.09%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
Landos Biopharma stock price monthly change
+6.65%
month
Landos Biopharma stock price quarterly change
+324.63%
quarter
Landos Biopharma stock price yearly change
+6869.60%
year
Landos Biopharma key metrics
Market Cap | 71.67M |
Enterprise value | N/A |
P/E | -0.29 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.29 |
PEG ratio | -0.07 |
EPS | -3.98 |
Revenue | N/A |
EBITDA | -25.20M |
Income | -24.79M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLandos Biopharma stock price history
Landos Biopharma stock forecast
Landos Biopharma financial statements
| Jun 2023 | 0 | -3.92M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.86M | |
| Dec 2023 | 0 | -6.11M | |
| Mar 2024 | 0 | -8.89M |
| Mar 2024 | 0 | -8.89M | |
|---|---|---|---|
| Sep 2025 | 0 | -2.85M | |
| Oct 2025 | 0 | -2.85M | |
| Dec 2025 | 0 | -3.10M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 46285000 | 3.01M | 6.51% |
|---|---|---|---|
| Sep 2023 | 43230000 | 5.56M | 12.88% |
| Dec 2023 | 38040000 | 6.24M | 16.43% |
| Mar 2024 | 29896000 | 6.74M | 22.55% |
| Jun 2023 | -5.11M | 3.97M | -99K |
|---|---|---|---|
| Sep 2023 | -2.22M | 634K | 0 |
| Dec 2023 | -4.96M | 63K | -1.83M |
| Mar 2024 | -8.49M | 0 | 0 |
Landos Biopharma alternative data
| Aug 2023 | 22 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 22 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 19 |
| Apr 2024 | 19 |
| May 2024 | 19 |
| Jun 2024 | 19 |
| Jul 2024 | 19 |
Landos Biopharma other data
0.74%
-38.37%
of LABP is owned by hedge funds
297.86K
-15.44M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 0 | 300000 |
| Jan 2023 | 30909090 | 0 |
| Feb 2023 | 0 | 786299 |
| Patent |
|---|
Application Filling date: 20 May 2022 Issue date: 1 Sep 2022 |
Grant Filling date: 2 Aug 2021 Issue date: 5 Jul 2022 |
Application COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES Filling date: 17 Nov 2021 Issue date: 19 May 2022 |
Application Filling date: 2 Nov 2021 Issue date: 5 May 2022 |
Application Filling date: 20 Oct 2021 Issue date: 28 Apr 2022 |
Application Filling date: 20 Sep 2021 Issue date: 24 Mar 2022 |
Application Filling date: 12 Nov 2021 Issue date: 10 Mar 2022 |
Application Filling date: 29 Sep 2021 Issue date: 20 Jan 2022 |
Grant Filling date: 16 Nov 2018 Issue date: 14 Dec 2021 |
Grant Utility: PLXDC2 ligands Filling date: 25 Mar 2021 Issue date: 23 Nov 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2021 15 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Josep Bassaganya-Riera DVM, Ph.D. (1975) Advisor | $741,770 |
Ms. Jyoti Chauhan M.S. (1989) Executive Vice President of Clinical & Regulatory Affairs | $281,420 |
Dr. Raquel Hontecillas DVM, Ph.D. (1972) Chief Scientific Officer | $228,760 |
-
What's the price of Landos Biopharma stock today?
One share of Landos Biopharma stock can currently be purchased for approximately $22.91.
-
When is Landos Biopharma's next earnings date?
Unfortunately, Landos Biopharma's (LABP) next earnings date is currently unknown.
-
Does Landos Biopharma pay dividends?
No, Landos Biopharma does not pay dividends.
-
How much money does Landos Biopharma make?
Landos Biopharma has a market capitalization of 71.67M.
-
What is Landos Biopharma's stock symbol?
Landos Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "LABP".
-
What is Landos Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Landos Biopharma?
Shares of Landos Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Landos Biopharma's key executives?
Landos Biopharma's management team includes the following people:
- Dr. Josep Bassaganya-Riera DVM, Ph.D. Advisor(age: 50, pay: $741,770)
- Ms. Jyoti Chauhan M.S. Executive Vice President of Clinical & Regulatory Affairs(age: 36, pay: $281,420)
- Dr. Raquel Hontecillas DVM, Ph.D. Chief Scientific Officer(age: 53, pay: $228,760)
-
How many employees does Landos Biopharma have?
As Jul 2024, Landos Biopharma employs 19 workers.
-
When Landos Biopharma went public?
Landos Biopharma, Inc. is publicly traded company for more then 4 years since IPO on 4 Feb 2021.
-
What is Landos Biopharma's official website?
The official website for Landos Biopharma is landosbiopharma.com.
-
Where are Landos Biopharma's headquarters?
Landos Biopharma is headquartered at 1800 Kraft Drive, Blacksburg, VA.
-
How can i contact Landos Biopharma?
Landos Biopharma's mailing address is 1800 Kraft Drive, Blacksburg, VA and company can be reached via phone at +54 02182232.
Landos Biopharma company profile:
Landos Biopharma, Inc.
landosbiopharma.comExchange:
NASDAQ
Full time employees:
19
Industry:
Biotechnology
Sector:
Healthcare
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
1800 Kraft Drive
Blacksburg, VA 24060
Blacksburg, VA 24060
CIK: 0001785345
ISIN: US5150692011
CUSIP: 515069102
